製藥和生物製藥合約製造市場－全球產業規模、佔有率、趨勢、機會和預測（按產品類型、服務、地區和競爭細分，2020-2030 年）

2024 年全球製藥和生物製藥合約製造市場價值為 130.5 億美元，預計到 2030 年將達到 184.1 億美元，預測期內的複合年成長率為 6.10%。合約開發和製造組織 (CDMO) 已成為製藥和生物技術公司不可或缺的合作夥伴，提供藥物配方、活性藥物成分 (API) 生產和商業規模製造方面的能力。越來越多的公司將這些業務外包，以減少資本投資、加快產品上市速度，並在不斷變化的監管框架和市場條件下保持靈活性。這種趨勢在生物製藥領域尤其明顯，因為生產生物製劑、生物相似藥以及細胞和基因療法的複雜性需要先進的技術和嚴格的品質標準。儘管成長前景強勁，但市場參與者必須應對日益複雜的監管以及對合規基礎設施的持續投資。

關鍵市場促進因素

醫療保健產業的成長

主要市場挑戰

生物製藥製造的複雜性

主要市場趨勢

更關注細胞和基因治療製造

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：COVID-19 對全球製藥和生物製藥合約製造市場的影響

第5章：全球製藥和生物製藥合約製造市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按產品類型（活性藥物成分 (API)、成品劑型、先進藥物輸送產品、非處方 (OTC) 藥品、其他）
  • 按服務（製藥製造服務、生物製劑製造服務、藥物開發服務、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美製藥和生物製藥合約製造市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第7章：歐洲製藥和生物製藥合約製造市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太製藥和生物製藥合約製造市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲

第9章：南美洲製藥和生物製藥合約製造市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第10章：中東及非洲製藥及生物製藥合約製造市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 合併與收購（如有）
• 產品發布（如有）
• 最新動態

第13章：干擾：衝突、流行病與貿易壁壘

第 14 章：全球製藥和生物製藥合約製造市場：SWOT 分析

第 15 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 16 章：競爭格局

• Jubilant Pharmova Limited
• JRS PHARMA GmbH & Co.
• Boehringer Ingelheim GmbH
• Lonza Group
• Rentschler Biotechnologie GmbH
• Inno Biologics Sdn Bhd
• INCOG BioPharma Services
• Baxter Biopharma Solutions
• Catalent Pharma Solutions
• Kemwell Biopharma Private Limited

第 17 章：策略建議

第18章調查會社について,免責事項

The Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market was valued at USD 13.05 Billion in 2024 and is projected to reach USD 18.41 Billion by 2030, growing at a CAGR of 6.10% during the forecast period. Contract Development and Manufacturing Organizations (CDMOs) have become indispensable partners for pharmaceutical and biotechnology companies, offering capabilities in drug formulation, active pharmaceutical ingredient (API) production, and commercial-scale manufacturing. Increasingly, companies are outsourcing these operations to reduce capital investments, improve speed to market, and maintain agility in the face of evolving regulatory frameworks and market conditions. This trend is especially pronounced in the biopharmaceutical sector, where the complexity of producing biologics, biosimilars, and cell and gene therapies necessitates advanced technologies and rigorous quality standards. Although growth prospects are robust, market players must contend with rising regulatory complexity and the need for continuous investment in compliance infrastructure.

Key Market Drivers

Growth in Healthcare Industry

The rapid expansion of the global healthcare sector, generating over USD 4 trillion in annual revenue, is a significant growth driver for the pharmaceutical and biopharmaceutical contract manufacturing market. With pharmaceuticals and biotechnology contributing nearly USD 850 billion and medical technology and diagnostics adding over USD 400 billion, the healthcare industry is witnessing a growing need for efficient drug production and scalable manufacturing capabilities. To meet these demands, drug developers are increasingly outsourcing to CDMOs, allowing them to focus on R&D and commercialization while leveraging external partners' infrastructure and regulatory expertise. The high costs and long development timelines associated with new drug development-ranging between USD 314 million and USD 4.46 billion-further incentivize the use of contract manufacturers to manage costs, accelerate production, and ensure compliance with evolving regulatory standards.

Key Market Challenges

Complexity in Biopharmaceutical Manufacturing

Biopharmaceutical manufacturing presents considerable complexity, making it a critical challenge for contract manufacturing organizations. Unlike conventional small-molecule drugs, biopharmaceuticals-such as monoclonal antibodies, vaccines, and cell and gene therapies-are derived from living organisms, making their production highly sensitive to variables like temperature, pH, and raw material quality. This complexity necessitates precise control of upstream and downstream processes, as even minor deviations can compromise product safety and efficacy. Consequently, CDMOs must make substantial investments in advanced infrastructure, process optimization, and quality management systems. These demands often lead to longer development cycles and increased operational costs, requiring CDMOs to maintain high levels of expertise and resource allocation.

Key Market Trends

Increased Focus on Cell and Gene Therapy Manufacturing

A defining trend in the market is the rising focus on cell and gene therapy manufacturing. With 76 such therapies launched globally by the end of 2023-more than double the number from a decade prior-this segment is gaining traction due to its promise of targeted, curative treatments for complex diseases. Unlike traditional drug manufacturing, cell and gene therapies involve highly specialized, patient-specific processes that require stringent quality control, cutting-edge bioprocessing, and regulatory precision. Due to these challenges, pharmaceutical companies are increasingly partnering with CDMOs that possess proven capabilities in handling advanced therapeutic modalities. These partnerships enable faster development timelines, greater scalability, and improved regulatory compliance, reinforcing the role of CDMOs as strategic allies in the evolving therapeutic landscape.

Key Market Players

• Jubilant Pharmova Limited
• JRS PHARMA GmbH & Co.
• Boehringer Ingelheim GmbH
• Lonza Group
• Rentschler Biotechnologie GmbH
• Inno Biologics Sdn Bhd
• INCOG BioPharma Services
• Baxter Biopharma Solutions
• Catalent Pharma Solutions
• Kemwell Biopharma Private Limited

Report Scope

In this report, the Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmaceutical & Biopharmaceutical Contract Manufacturing Market, By Product Type:

• Active Pharmaceutical Ingredients (API)
• Finished Dosage Formulation
• Advanced Drug Delivery Products
• Over the Counter (OTC) Medicines
• Others

Pharmaceutical & Biopharmaceutical Contract Manufacturing Market, By Service:

• Pharmaceutical Manufacturing Services
• Biologics Manufacturing Services
• Drug Development Services
• Others

Pharmaceutical & Biopharmaceutical Contract Manufacturing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market.

Available Customizations

Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market

5. Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Active Pharmaceutical Ingredients (API), Finished Dosage Formulation, Advanced Drug Delivery Products, Over the Counter (OTC) Medicines, Others)
  • 5.2.2. By Service (Pharmaceutical Manufacturing Services, Biologics Manufacturing Services, Drug Development Services, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Service
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Service
  • 6.3.2. Mexico Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Service
  • 6.3.3. Canada Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Service

7. Europe Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Service
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Service
  • 7.3.2. Germany Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Service
  • 7.3.3. United Kingdom Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Service
  • 7.3.4. Italy Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Service
  • 7.3.5. Spain Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Service

8. Asia Pacific Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Service
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Service
  • 8.3.2. India Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Service
  • 8.3.3. South Korea Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Service
  • 8.3.4. Japan Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Service
  • 8.3.5. Australia Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Service

9. South America Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Service
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Service
  • 9.3.2. Argentina Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Service
  • 9.3.3. Colombia Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Service

10. Middle East and Africa Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Service
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Service
  • 10.3.2. Saudi Arabia Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Service
  • 10.3.3. UAE Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Service

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market: SWOT Analysis

15. Porters Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. Jubilant Pharmova Limited
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. JRS PHARMA GmbH & Co.
• 16.3. Boehringer Ingelheim GmbH
• 16.4. Lonza Group
• 16.5. Rentschler Biotechnologie GmbH
• 16.6. Inno Biologics Sdn Bhd
• 16.7. INCOG BioPharma Services
• 16.8. Baxter Biopharma Solutions
• 16.9. Catalent Pharma Solutions
• 16.10. Kemwell Biopharma Private Limited

17. Strategic Recommendations

18. About Us & Disclaimer